Below is a pipeline of potential therapies for myotonic dystrophy being developed by pharmaceutical companies, hospitals and universities. The table includes therapies in early laboratory development all the way up to early and late clinical development.

Our grateful thanks to Ben Porter of the UK DM Patient Registry for compiling this information and for allowing us to share it.

(Latest update 24/05/21)